Celldex

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Celldex and other ETFs, options, and stocks.

About CLDX

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. 

CEO
Anthony S. Marucci
CEOAnthony S. Marucci
Employees
198
Employees198
Headquarters
Hampton, New Jersey
HeadquartersHampton, New Jersey
Founded
1983
Founded1983
Employees
198
Employees198

CLDX Key Statistics

Market cap
2.89B
Market cap2.89B
Price-Earnings ratio
-8.72
Price-Earnings ratio-8.72
Dividend yield
Dividend yield
Average volume
1.82M
Average volume1.82M
High today
$37.64
High today$37.64
Low today
$36.78
Low today$36.78
Open price
$37.15
Open price$37.15
Volume
141.75K
Volume141.75K
52 Week high
$39.16
52 Week high$39.16
52 Week low
$19.72
52 Week low$19.72

Stock Snapshot

The current Celldex(CLDX) stock price is $36.78, with a market capitalization of 2.89B. The stock trades at a price-to-earnings (P/E) ratio of -8.72.

On 2026-07-01, Celldex(CLDX) stock traded between a low of $36.78 and a high of $37.64. Shares are currently priced at $36.78, which is 0.0% above the low and -2.3% below the high.

Celldex(CLDX) shares are trading with a volume of 141.75K, against a daily average of 1.82M.

During the past year, Celldex(CLDX) stock moved between $19.72 at its lowest and $39.16 at its peak.

During the past year, Celldex(CLDX) stock moved between $19.72 at its lowest and $39.16 at its peak.

CLDX News

Investing.com 2d
Celldex Therapeutics stock hits 52-week high at 35.8 USD - Investing.com

...

Celldex Therapeutics stock hits 52-week high at 35.8 USD - Investing.com
TipRanks 5d
Celldex Shareholders Approve Expanded Equity Incentive Plan

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...

Simply Wall St 5d
Celldex Therapeutics Is Up 5.1% After Barzolvolimab, CDX-622 Mast-Cell Data Update - What's Changed

Earlier in June, Celldex Therapeutics reported at the European Academy of Allergy and Clinical Immunology meeting that barzolvolimab produced rapid, durable and...

Celldex Therapeutics Is Up 5.1% After Barzolvolimab, CDX-622 Mast-Cell Data Update - What's Changed

Analyst ratings

94%

of 16 ratings
Buy
93.8%
Hold
6.3%
Sell
0%

People also own

Based on the portfolios of people who own CLDX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.